1-cyclohexyl-3-[[oxo(thiophen-2-yl)methyl]amino]thiourea is a complex organic molecule with a specific structure. It is a **thiourea derivative** containing a cyclohexyl group, a thiophene ring, and an amide group.
**Why it is important for research:**
While there isn't a lot of publicly available information specifically about this molecule, its structural features suggest it could be investigated for several reasons:
* **Biological Activity:** Thiourea derivatives have been studied for their potential **biological activity** in areas like:
* **Antimicrobial activity:** Some thioureas have shown efficacy against bacteria, fungi, and even viruses.
* **Antioxidant activity:** Thiourea derivatives can act as radical scavengers, potentially protecting against oxidative damage.
* **Anti-inflammatory activity:** Certain thioureas have been linked to reducing inflammation.
* **Pharmacological applications:** The presence of a thiophene ring is common in compounds with pharmacological activity, like:
* **Anticonvulsants**
* **Anti-inflammatory agents**
* **Antibiotics**
* **Synthesis and Chemistry:** The molecule's complexity makes it potentially interesting for:
* **Studying chemical reactions and synthetic pathways**
* **Exploring structure-activity relationships**
**Important Note:** The research potential of this specific molecule needs to be investigated further. It's vital to perform experimental studies to determine its actual properties and potential applications.
**To further research:**
* Search for publications related to thiourea derivatives and thiophene ring containing compounds.
* Look for information about biological activity and pharmacological properties of similar structures.
* Explore databases of chemical compounds and their properties.
Remember, the information here is based on the chemical structure and general knowledge about thiourea derivatives. More specific research is necessary to confirm its actual importance and applications.
ID Source | ID |
---|---|
PubMed CID | 727045 |
CHEMBL ID | 1536376 |
CHEBI ID | 120687 |
Synonym |
---|
AA-768/32303032 |
n-cyclohexyl-2-(2-thienylcarbonyl)hydrazinecarbothioamide |
MLS000699942 |
smr000224513 |
CHEBI:120687 |
AKOS005106975 |
1-cyclohexyl-3-(thiophene-2-carbonylamino)thiourea |
HMS2521O05 |
n-{[(cyclohexylamino)thioxomethyl]amino}-2-thienylcarboxamide |
1-(2-thienylcarbonyl)-4-cyclohexylthiosemicarbazide |
n-[(cyclohexylcarbamothioyl)amino]thiophene-2-carboxamide |
331461-23-5 |
JS-0596 |
CHEMBL1536376 |
Q27208821 |
1-cyclohexyl-3-[[oxo(thiophen-2-yl)methyl]amino]thiourea |
SR-01000307735-1 |
sr-01000307735 |
mfcd00169633 |
n-cyclohexyl-2-(2-thienylcarbonyl)-1-hydrazinecarbothioamide |
n-cyclohexyl-2-(thiophene-2-carbonyl)hydrazinecarbothioamide |
Class | Description |
---|---|
thiophenes | Compounds containing at least one thiophene ring. |
aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 0.7079 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 2.5119 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
P53 | Homo sapiens (human) | Potency | 70.7946 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 7.0795 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 2.8184 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 1.4125 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 28.1838 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
protein binding | Glycoprotein hormones alpha chain | Homo sapiens (human) |
follicle-stimulating hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
extracellular region | Glycoprotein hormones alpha chain | Homo sapiens (human) |
extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
Golgi lumen | Glycoprotein hormones alpha chain | Homo sapiens (human) |
follicle-stimulating hormone complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
pituitary gonadotropin complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |